Invivyd, a biopharmaceutical company centered on protection against viral infectious diseases, is naming Michael Mina, MD, PhD, chief medical officer. Invivyd’s proprietary integrated technology platform, according to the company, is unique to the industry. It assesses, monitors, develops, and adapts to create best-in-class antibodies. In recent years, the company’s focus has been SARS-CoV-2. In March 2024, Invivyd received emergency use authorization from the U.S. FDA for a monoclon...